skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.10e (Release date: 2017-10-30)
SearchBox Top
SearchBox Bottom
Quisinostat (Code C77912)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Quisinostat

Definition: An orally bioavailable, second-generation, hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. HDAC inhibitor JNJ-26481585 inhibits HDAC leading to an accumulation of highly acetylated histones, which may result in an induction of chromatin remodeling; inhibition of the transcription of tumor suppressor genes; inhibition of tumor cell division; and the induction of tumor cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins. Compared to some first generation HDAC inhibitors, JNJ-26481585 may induce superior HSP70 upregulation and bcl-2 downregulation.

Display Name: Quisinostat

Label: Quisinostat

NCI Thesaurus Code: C77912 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2703097  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
HDAC Inhibitor JNJ-26481585

External Source Codes: 
CAS Registry Number 875320-29-9 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 596704
PDQ Open Trial Search ID 596704 (check for NCI PDQ open clinical trial info)
UMLS CUI C2703097

Other Properties:
     Name Value (qualifiers indented underneath)
Chemical_Formula C21H26N6O2
code C77912
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name HDAC_Inhibitor_JNJ-26481585
Semantic_Type Organic Chemical
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom